Press release
Diabetic Peripheral Neuropathy Market size in the 7MM was approximately USD 2,740 million in 2022, estimated DelveInsight
Discover Key Insights into the Diabetic Peripheral Neuropathy Market with DelveInsight's In-Depth Report @ Diabetic Peripheral Neuropathy Market Size [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Diabetic Peripheral Neuropathy Market Report
* In 2023, the highest number of type-specific cases of diabetic neuropathy were observed for peripheral diabetic neuropathy in the 7MM.
* The total prevalent cases of diabetic peripheral neuropathy in the 7MM were around 34,000,000 cases in 2023 out of which the highest prevalent cases of this disease were seen in the United States.
* Among EU4 and the UK, Germany accounted for the highest cases of the total prevalent cases of diabetic neuropathy, whereas Spain accounted for the least number of cases.
* The US accounted for nearly 50% of total treated cases in 2023, which is expected to increase by 2034.
* The leading Diabetic Peripheral Neuropathy Companies such as Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grunenthal GmbH, Glenmark Pharmaceuticals, and others.
* Promising Diabetics Peripheral Neuropathy Therapies such as LY3556050, Engensis, Suzetrigine, Pregabalin , and others.
Stay ahead in the Diabetic Peripheral Neuropathy Therapeutics Market with DelveInsight's Strategic Report @ Diabetic Peripheral Neuropathy Market Outlook [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Diabetic Peripheral Neuropathy Epidemiology Segmentation in the 7MM
* Diabetic Peripheral Neuropathy Prevalent Cases
* Diabetic Peripheral Neuropathy Treated Cases
* Diabetic Peripheral Neuropathy Prevalent Cases of Painful
Download the report to understand which factors are driving Diabetic Peripheral Neuropathy epidemiology trends @ Diabetic Peripheral Neuropathy Prevalence [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Diabetic Peripheral Neuropathy Marketed Drugs
* QUTENZA (capsaicin): Grunenthal/Averitas Pharma
QUTENZA (capsaicin), developed by Grunenthal and Averitas Pharma, is an 8% topical system that contains capsaicin in a localized dermal delivery system. Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations. In July 2020, Grunenthal's US subsidiary Averitas Pharma received US FDA approval for a QUTENZA (capsaicin) 8% patch for treating neuropathic pain associated with Diabetic Peripheral Neuropathy of the feet in adults.
* TARLIGE (mirogabalin besylate): Daiichi Sankyo
TARLIGE (mirogabalin besylate) is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain, including diabetic Peripheral Neuropathic pain and postherpetic neuralgia. In January 2019, Daiichi Sankyo announced the approval of TARLIGE for marketing in Japan for the treatment of Diabetic Peripheral Neuropathy and expects the drug to benefit patients in Japan by providing a new therapeutic option for the treatment of Peripheral Neuropathy Pain.
Diabetic Peripheral Neuropathy Emerging Drugs
* Engensis (VM202): Helixmith
Engensis (VM202), developed by Helixmith is a DNA-based drug designed to produce two isoforms of HGF (hepatocyte growth factor), HGF728 and HGF723. When VM202 is delivered to the affected area by a single intramuscular injection, this drug enters a small portion of the surrounding muscle cells. In the case of Diabetic Peripheral Neuropathy, it has the potential to reverse the underlying cause of neuropathy through an angio-neurorestorative effect, without simply managing the pain. This drug is currently in Phase III developmental stage and has been granted RMAT (Regenerative Medicine Advanced Therapy) designation by the US FDA in 2018.
* Suzetrigine (VX-548): Vertex Pharmaceuticals
VX-548 being developed by Vertex Pharmaceuticals is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the treatment of pain and multiple pain indications including acute pain, and neuropathic pain. It is currently in Phase III development stage.
Get In-Depth Knowledge on Diabetic Peripheral Neuropathy Market Trends and Forecasts with DelveInsight @ Diabetic Peripheral Neuropathy Treatment Market [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Diabetic Peripheral Neuropathy Market Outlook
Treatment modalities focus on optimized diabetic management and symptomatic relief. Glycemic control is the first step in the approach to disease management and has been shown to improve the occurrence of falls and the presence of foot ulcers. The three main principles of treatment for peripheral neuropathy are glycemic control, foot care, and pain management. The prescription medicines commonly used for managing diabetic peripheral neuropathy pain include Gabapentin and Pregabalin, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Opioids. Other Alternatives include Antiseizure Medications like carbamazepine or lamotrigine.
Diabetic Peripheral Neuropathy Drugs Uptake
Suzetrigine (VX-548), under development by Vertex Pharmaceuticals, holds promise as a potential game-changer in the treatment landscape of diabetic peripheral neuropathy. Positioned as an oral, selective NaV1.8 inhibitor, Suzetrigine boasts high selectivity for NaV1.8 over other NaV channels, enhancing its therapeutic potential. Its Phase III development stage underscores its advancement towards market entry. The oral route of administration offers a distinct advantage, ensuring ease of uptake for patients compared to alternative pipeline drugs. Moreover, Suzetrigine's mechanism of action aligns with addressing neuropathic pain effectively.
Unlock Strategic Insights with DelveInsight's Comprehensive Diabetic Peripheral Neuropathy Market Report @ Diabetic Peripheral Neuropathy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Diabetic Peripheral Neuropathy Market Report
* Coverage- 7MM
* Diabetic Peripheral Neuropathy Companies- Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grunenthal GmbH, Glenmark Pharmaceuticals, and others.
* Diabetics Peripheral Neuropathy Therapies- LY3556050, Engensis, Suzetrigine, Pregabalin, and others.
* Diabetic Peripheral Neuropathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Diabetic Peripheral Neuropathy Unmet Needs, KOL's views, Analyst's views, Diabetic Peripheral Neuropathy Market Access and Reimbursement
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 Diabetic Peripheral Neuropathy Market Overview at a Glance
7 Disease Background and Overview
8 Treatment and Management
9 Epidemiology and Patient Population of Diabetic Peripheral Neuropathy in the 7MM
10 Patient Journey
11 Marketed Therapies
Full list of marketed drugs will be provided in the report
12 Emerging Therapies
Full list of emerging drugs will be provided in the report
13 Diabetic Peripheral Neuropathy: 7MM Market Analysis
14 Unmet Needs
15 SWOT Analysis
16 KOL Views
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-peripheral-neuropathy-market-size-in-the-7mm-was-approximately-usd-2740-million-in-2022-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Peripheral Neuropathy Market size in the 7MM was approximately USD 2,740 million in 2022, estimated DelveInsight here
News-ID: 3755310 • Views: …
More Releases from ABNewswire
Are users still looking for the perfect affordable POS solution for their busine …
Tablets POS will be the good choice for you . It has large touch screens, better visibility, and accessibility, and with the technological improvements of recent years, the powerful processors is allowing them to run complex apps.
However, a tablet point-of-sale [https://www.hosoton.com/h101-android-10-1inch-biometric-tablet-pc-for-digital-fintech-industry-product/] is not complex, nor difficult to use - in fact, you can use these incredible tools to create a technological infrastructure in your restaurant or hospitality easily.
Image: https://www.hosoton.com/uploads/Tablet-payment-pos-system-for-customer-display.jpg
In this…
Which Indoor LED Screen Types Offer the Best Resolution and Flexibility for Mode …
Indoor LED Screen Trends in Modern Commercial Spaces
The use of indoor LED screens is growing quickly in today's commercial areas. Businesses now want clearer pictures and more adaptable display setups. These screens appear in places like company offices, big stores, museums, and religious sites. They are not just fixed setups anymore. Instead, they serve as lasting visual tools that fit changing designs and content plans. This change makes buyers look…
What are the Functions of the Otis Elevator Test Tool?
The Otis test tool [https://www.nonaelevator.com/elevator-service-test-tools-otis-gaa21750ak3-lift-commissioning-operator-product/] is a powerful assistant in the elevator commissioning process, boasting a rich array of button functions and easy operation. To help you better understand and use this commissioning tool, we have compiled the following button function descriptions to make your Otis elevator drive process more efficient.
First, let's look at the four key buttons on the left: MODULE, FUNCTION, SET, and the blue button. The commissioning…
Optical Fibers: Riding the 2026 Wave of Recovery & High-Growth
In 2026, the optical fiber cable industry stands at a pivotal crossroads. After years of market adjustments, ordinary optical fibers [https://www.oyii.net/central-loose-tube-non-metallic-non-armored-fiber-optic-cable-product/] are witnessing a 15% price rebound since May 2025, with carrier prices (carrier procurement prices) expected to follow suit. Meanwhile, specialty fibers like submarine cables and military-grade cables are emerging as profit powerhouses, boasting over 20% net profit margins. This dual momentum-recovery in general fibers and surge in specialty…
More Releases for Peripheral
Key Trends Reshaping the Peripheral Arterial Disease Market: Innovative Shockwav …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Peripheral Arterial Disease Market Size Growth Forecast: What to Expect by 2025?
The overall valuation of the peripheral arterial disease sector has seen substantial expansion lately, projected to climb from $4.36 billion recorded in 2024 to reach $4.74 billion by 2025, reflecting an 8.7% compound annual growth rate over…
Peripheral Stent Market - Pioneering Solutions for Peripheral Artery Disease: Re …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Peripheral Stent Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Peripheral Stent provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes both intuitive…
Peripheral Vascular Devices Market - Empowering Mobility, Preserving Health: Ele …
Newark, New Castle, USA - new report, titled Peripheral Vascular Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Peripheral Vascular Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Peripheral Vascular Devices market. The report offers an overview of…
Peripheral Vascular Devices Market Report 2018: Segmentation by Types (Periphera …
Global Peripheral Vascular Devices market research report provides company profile for Abbott Vascular, Bayer Healthcare, Volcano Corporation, Teleflex Medical and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation…
Peripheral Vascular Device Market Size, Peripheral Vascular Device Market Share, …
Global Peripheral Vascular Device Market Size is observed to gain traction owing to the factors such as increasing research and development for developing several new product, and rising funding by the private organizations.
Request for Sample of This Research Report @ https://bit.ly/2xjOKpC
Top Key Player:-
Abbott Laboratories
Braun Melsungen AG
Boston Scientific Corporation
R. Brad, Inc.
Cardinal Health, Inc.
Medtronic plc.
Cook Medical, Inc.
Teruma Corporation
Jude Medical, Inc.
The Spectranetics Corporation
Volcano Corporation
Peripheral vascular disorder (PVD) is a blood circulation disorder…
Peripheral Artery Disease Market By Type (Peripheral Angioplasty Balloons, Perip …
Peripheral artery disease is characterized by plaque built up in the arteries carrying blood from heart to legs, arms, and other limbs. Peripheral artery disease in turn also increases the risk of other cardiovascular disorders such as heart attack, coronary heart disease, stroke, and ischemic attack.
Request Sample At: https://www.bigmarketresearch.com/request-sample/1633533
The global peripheral artery disease market generated $3,136 million in 2016, and is projected to reach $4,980 million by 2023, registering a…
